{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:47:50Z","timestamp":1765738070654,"version":"3.48.0"},"reference-count":20,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"crossref","award":["ASP-1502-27029"],"award-info":[{"award-number":["ASP-1502-27029"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate whether the effectiveness and safety of low (81 mg daily) versus high-dose (325 mg daily) aspirin is consistent across races among patients with established atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A secondary analysis of the randomised controlled trial ADAPTABLE was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study was conducted in 40 centres and one health plan participating in the National Patient-Centred Clinical Research Network (PCORnet) in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Among 15 076 participants with established ASCVD, 14 096 had self-reported race available and were included in the analysis. Participants were divided according to self-reported race as Black (n=1311, 9.3%), White (n=11 990, 85.1%) or other race (n=795, 5.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Participants were randomised to open-label daily aspirin doses of 81 mg versus 325 mg in a 1:1 ratio for a median of 26.2 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes measures<\/jats:title>\n                    <jats:p>The primary effectiveness endpoint was a composite of death from any cause, hospitalisation for myocardial infarction or hospitalisation for stroke. The primary safety endpoint was hospitalisation for bleeding requiring blood product transfusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Estimated cumulative incidence of the primary effectiveness endpoint at median follow-up with the 81 mg and the 325 mg daily doses were 6.70% and 7.12% in White participants (adjusted HR: 1.00 [95% CI: 0.88 to 1.15]); 12.27% and 10.69% in Black participants (adjusted HR: 1.40 [95% CI: 1.02 to 1.93]); and 6.88% and 7.69% in other participants (adjusted HR: 0.86 [95% CI: 0.54 to 1.39]) (p-interaction=0.12), respectively. There was no significant interaction between self-reported race and assigned aspirin dose regarding the secondary effectiveness and the primary safety endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Race is not an effect modifier on the impact of aspirin dosing on effectiveness and safety in patients with established ASCVD. In clinical practice, treatment decisions regarding aspirin dose in secondary prevention of ASCVD should not be influenced by race.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial results\" xlink:href=\"NCT02697916\">NCT02697916<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-078197","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:51:16Z","timestamp":1723089076000},"page":"e078197","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct02697916","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct02697916","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2965-1504","authenticated-orcid":false,"given":"Guillaume","family":"Marquis-Gravel","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Mulder","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1732-9067","authenticated-orcid":false,"given":"Lisa M","family":"Wruck","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine P","family":"Benziger","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Essentia Health, Duluth, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B","family":"Effron","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, New Orleans, Louisiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M","family":"Farrehi","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saket","family":"Girotra","sequence":"additional","affiliation":[{"name":"University Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Kripalani","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar S","family":"Polonsky","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-838X","authenticated-orcid":false,"given":"Jeff","family":"Whittle","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Harrington","sequence":"additional","affiliation":[{"name":"Stanford University, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Rothman","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke University, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WS","family":"Jones","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"2025121410442036000_14.8.e078197.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7."},{"key":"2025121410442036000_14.8.e078197.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001437"},{"key":"2025121410442036000_14.8.e078197.3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamacardio.2019.4845","article-title":"Temporal trends in racial differences in 30-day readmission and mortality rates after acute myocardial infarction among medicare beneficiaries","volume":"5","author":"Pandey","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025121410442036000_14.8.e078197.4","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009013"},{"key":"2025121410442036000_14.8.e078197.5","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22570"},{"key":"2025121410442036000_14.8.e078197.6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.121.011171","article-title":"Racial disparities in invasive management for patients with acute myocardial infarction with chronic kidney disease","volume":"15","author":"Rymer","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"2025121410442036000_14.8.e078197.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.024"},{"key":"2025121410442036000_14.8.e078197.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"2025121410442036000_14.8.e078197.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810273191701"},{"key":"2025121410442036000_14.8.e078197.10","doi-asserted-by":"crossref","unstructured":"Arnett DK , Blumenthal RS , Albert MA , et al . ACC\/AHA guideline on the primary prevention of cardiovascular disease. 2019. doi:10.1001\/jamacardio.2019.2604","DOI":"10.1001\/jamacardio.2019.2604"},{"key":"2025121410442036000_14.8.e078197.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.012"},{"key":"2025121410442036000_14.8.e078197.12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15829\/1560-4071-2020-2-3757","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"25","author":"Knuuti","year":"2019","journal-title":"Russ J Cardiol"},{"key":"2025121410442036000_14.8.e078197.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2025121410442036000_14.8.e078197.14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11239-020-02327-w","article-title":"Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans","volume":"51","author":"Infeld","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2025121410442036000_14.8.e078197.15","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121410442036000_14.8.e078197.16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2020.0116","article-title":"Rationale and design of the aspirin dosing-a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE) Trial","volume":"5","author":"Marquis-Gravel","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2025121410442036000_14.8.e078197.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025121410442036000_14.8.e078197.18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/17407745221118559","article-title":"Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience","volume":"20","author":"Marquis-Gravel","year":"2023","journal-title":"Clin Trials"},{"key":"2025121410442036000_14.8.e078197.19","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0000000000000949","article-title":"Exploring meaningful patient engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness)","volume":"56 Suppl 10 Suppl 1","author":"Faulkner","year":"2018","journal-title":"Med Care"},{"key":"2025121410442036000_14.8.e078197.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052717"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-078197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:44:28Z","timestamp":1765737868000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-078197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,7]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2023-078197"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-078197","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}